Docetaxel has shown to improve survival and quality of life in patients with castration-resistant prostate cancer. Its place as first-line treatment in this population is challenged by new hormonal treatments, but it still has a place in this setting. Its role in metastatic hormone-sensitive prostate cancer is becoming clearer and docetaxel may be offered to selected patients. In localised high-risk prostate cancer the place of docetaxel remains to be determined.
(BELG J MED ONCOL 2015;9(5):191–93)